Here is an overview of each medicine to help guide you and your physician when making a treatment decision for Cystic Fibrosis:
kalydeco
-
-
February 28, 2019
Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years.